CRISPR Therapeutics AG (CRSP) Operating Margin (2016 - 2026)

CRISPR Therapeutics AG has disclosed Operating Margin across 11 years of filings, most recently posting 8933.33% for Q1 2026.

• Operating Margin for Q1 2026 came in at 8933.33%, up 822551.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 15754.2% (down 1449501.0% YoY), and the FY2025 annual result was 18933.65%, down 1768327.0% from the prior year.
• Operating Margin came in at 8933.33% for Q1 2026 at CRISPR Therapeutics AG, up from 17912.5% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 34.58% in Q4 2023 to a low of 2192350.0% in Q4 2022.
• The 5-year median for Operating Margin is 18103.26% (2024), against an average of 167590.53%.
• Across the five-year window, Operating Margin slumped 219122047 bps in 2022 and jumped 219238458 bps in 2023, its largest moves.
• CRISPR Therapeutics AG's Operating Margin stood at 2192350.0% in 2022, then surged by 100 bps to 34.58% in 2023, then slumped by 623 bps to 180.96% in 2024, then tumbled by 9798 bps to 17912.5% in 2025, then jumped by 50 bps to 8933.33% in 2026.
• The last three Operating Margin figures came in at 8933.33% (Q1 2026), 17912.5% (Q4 2025), and 14854.78% (Q3 2025), per Business Quant data.